The first trial was a phase I-II dose escalating multicenter study of ofatumumab in 33 patients with R/R CLL who had received a median of 3 prior treatment regimens. They reported an overall response rate (ORR) of 48% (13 of 27 patients) with no complete responses (CR). The median progression-free survival (PFS) was 106 days. Grade 3 or more adverse events included infection, thrombocytopenia and neutropenia. The second trial was a phase II international trial using ofatumumab in fludarabine-and alemtuzumab-refractory (FA-ref) CLL In this issue, Moreno and colleagues 5 conducted a study on behalf of the European Research Initiative on CLL (ERIC group) in response to the conditional authorization of the drug in Europe. They report the results of a phase IV, noninterventional, observational study on single agent ofatumumab in poor-prognosis CLL. Notably, they were not able to reproduce similar ORR to that demonstrated by Coiffier et al. 3 and Wierda et al. 4 which raises questions over the use of ofatumumab as monotherapy in R/R CLL. One hundred and three patients with R/R CLL who had received a median of 4 prior treatment regimens were reported to have an ORR based on an intention-to-treat (ITT) of 22% (3CR, 1CR incomplete, 19PR). This is less than half that observed in the two pivotal trials upon which both FDA and EMA approval was obtained, despite consisting of patients with similar disease-risk profile. Median PFS and OS times were 5 and 11 months, respectively. These were shorter than those reported by Wierda et al. (6 and 14 months, respectively). 4 The adverse event profile is comparable to that seen in the two previous trials and included infusion-related reactions, cytopenias, and infections. Two patients developed PML.
With the introduction of novel therapies, the Bruton tyrosine kinase (Btk) inhibitor, ibrutinib, was compared directly with ofatumumab in a randomized clinical trial in this setting of R/R CLL. Ibrutinib demonstrated markedly improved duration of PFS, OS and response rates when compared to ofatumumab monotherapy. Byrd et al. 6 published a report last year showing their results at a median follow up of 9.4 months; the median duration of PFS was not reached in the ibrutinib group (88% at 6 months) as compared to a median PFS of 8.1 months in the ofatumumab group. OS at 12 months was 90% and 81% in the ibrutinib and ofatumumab groups, respectively. ORRs were significantly higher in the ibrutinib group (43% vs. 4%) consisting of only partial responses. Grade 3 or more adverse events included neutropenia (16% ibrutinib vs. 14% ofatumumab), anemia (5% ibrutinib vs. 8% ofatumumab), and pneumonia (7% ibrutinib vs. 5% ofatumumab). In the light of the efficacy and safety data of ibrutinib, it now has FDA and EMA approval for use in previously treated CLL. Given the efficacy seen with ibrutinib, the role of single agent ofatumumab in R/R setting now appears questionable (Table 1) .
Other roles of ofatumumab in R/R CLL are being explored, particularly combination studies (bendamustine and ofatumumab; 7 dexamethasone and ofatumumab; 8 lenalidomide and ofatumumab 9 ) and in maintenance studies 10 which do look promising (Table 2) , and these are likely to map out future treatment options in this setting.
Ofatumumab in first-line treatment for chronic lymphocytic leukemia
The use of ofatumumab in combination with chemotherapy (fludarabine (F) and cyclophosphamide (C)) in fit, treatment-naïve CLL patients has been discouraging, represented by a lower ORR than its counterpart monoclonal anti-CD20 antibody, rituximab, in combination with the same chemotherapy (FCR: ORR 90%, CR 44%). 11, 12 The ORR and CR for the 500 mg and the 1000 mg ofatumumab cohorts were 77% versus 73% and 32% versus 50%, respectively. Wierda et al. 12 postulate that the reduced ORR may reflect the proportion of higher-risk profiles of the patient population [13% 17p deletion and 64% Beta(b)-2-microglobulin (b2M) >3.5mg/L]. However, even though there was a lower proportion of patients with del(17p) in the FCR group (8%) 11 but with O-FC, the ORR and CR in patients with b2M>4mg/L were 68% and 29%, respectively. Interestingly, the O-FC group also had a higher rate of neutropenia when compared to that seen in FCR treated patients.
Hillmen et al. 13 examined the use of ofatumumab plus chlorambucil (Clb) versus chlorambucil monotherapy in treatment-naive patients in whom fludarabine-based therapy was deemed inappropriate (due to advanced age or comorbidities). They reported promising ORR and CR of 82% and 12%, respectively, with the combination of O-Clb compared to 69% and 1% with Clb alone. The median PFS was significantly longer with the addition of ofatumumab (22.4 vs. 13.1 months). Median overall survival (OS) was not reached at a median follow up of 29 months for either group. In April 2014, FDA approved the use of ofatumumab for patients in this setting. Late in 2014, Goede et al. 14, 15 published data on the anti-CD20 antibodies, rituximab (R) and obinutuzumab (G) in combination with chlorambucil in a similar patient cohort that had significant morbidity or a creatinine clearance between 30 and 69 mL/min. G-Clb compared to Clb alone had a significantly longer median PFS (29.9 vs. 11.1 months). Similarly, R-Clb compared to Clb alone had a significantly longer median PFS (16. group of frail patients, but this is unlikely to occur in the present environment where currently planned trials with obinutuzumab with either ibrutinib or Abt-199 are starting in this setting. In summary, in the R/R CLL setting, the role of ofatumumab as monotherapy has been superseded by novel agents, and, more specifically, with ibrutinib showing substantially superior activity in a direct comparison. 6 However, there may be an emerging role for ofatumumab in combination therapies and in maintenance. In the fit, treatment naïve CLL patient, FCR remains standard of care given the lower efficacy rates seen with O-FC. In the unfit, treatment-naïve CLL patient, despite having received FDA approval, the current use of ofatumumab in combination with Clb is not clear, given the demonstrated improved efficacy with the combination of obinutuzumab and Clb. I n this issue of Haematologica, Gorin and colleagues compare the outcomes after T-cell-replete haploidentical transplantation and autologous transplantation for adults with acute myeloid or lymphoblastic leukemia. 1 Following induction of complete remission, most adults with acute myeloid or lymphoblastic leukemia are referred for hematopoietic cell transplantation. However, donor choice varies. There is general agreement that an HLAmatched sibling is the most suitable donor. As only about a third of patients who may benefit from hematopoietic cell transplantation have an HLA-matched sibling donor, alternative donor choices include mismatched relatives, unrelated donors (volunteer adults or umbilical cord blood) or self (autologous). In the report by Gorin and colleagues, 1 overall and leukemia-free survival rates after T-cell-replete haploidentical and autologous transplantation were comparable when the haploidentical transplants were performed at experienced transplant centers defined as performing five or more haploidentical transplants over a 6-year period. When haploidentical transplants were performed at centers that performed fewer such transplants, overall and leukemiafree survival rates were better after autologous transplantation.
Selecting a suitable donor for hematopoietic cell transplantation requires careful review of the available literature. A recent report from the National Marrow Donor Program suggests most Caucasians will have an HLAmatched adult unrelated donor or one who is HLA-mismatched at a single locus. 2 However, use of T-cell-replete grafts from haploidentical donors is appealing and increasingly offered to patients. But transplant conditioning regimens and graft-versus-host disease prophylaxis vary by graft source and center practice. Consequently, in the absence of appropriately designed clinical trials, comparison and interpretation of outcomes between donor sources are challenging. Gorin and colleagues recommend autolo-
